Evidence map›Paper›PMID 34804792›Full record

ArticleLeukemia research reports2021

Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era.

Khadega A Abuelgasim, Samer Ghazi, Bader Alahmari, Ayman Alhejazi, Ahmed Alaskar, Mohsen Alzahrani, Moussab Damlaj

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Khadega A AbuelgasimDepartment of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Samer GhaziDepartment of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Bader AlahmariDepartment of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Ayman AlhejaziDepartment of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Ahmed AlaskarDepartment of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Mohsen AlzahraniDepartment of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Moussab DamlajDepartment of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
King Abdulaziz Medical City · SAKing Abdullah International Medical Research Center · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients refractory to first line salvage have poor outcomes. Herein we report the outcome of R/R cHL patients requiring ≥two vs. one line in the era of chemo-immunotherapy. Among 55 R/R cHL patients, 33 (60%) required one, 22 (40%) required ≥two lines. At 2 years, the estimated PFS and OS for patients requiring one vs. ≥two lines was 71.2% (50.1-84.7) vs. 51.9% (27.6-71.6),

Indexed as

Autologous stem cell transplantBrentuximab vedotinRelapsed refractory Hodgkin lymphomaSalvage chemotherapy

Identifiers

PMID34804792
PMCPMC8581367
OpenAlexW3207404257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.